Efficacy and Safety of Lu-177-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

Yadav Madhav Prasad; Ballal Sanjana; Bal Chandrashekhar; Sahoo Ranjit Kumar; Damle Nishikant Avinash; Tripathi Madhavi; Seth Amlesh

首页> 外文期刊>Clinical nuclear medicine >Efficacy and Safety of Lu-177-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

【24h】

Efficacy and Safety of Lu-177-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

机译：Lu-177-PSMA-617放射性配体治疗转移阉割前列腺癌患者的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: The aim of this study was to evaluate the efficacy and safety of Lu-177-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC).

机译：目的：本研究的目的是评估Lu-177-PSMA-617放射性配体治疗在转移性阉割的前列腺癌（MCRPC）中的疗效和安全性。

著录项

来源
《Clinical nuclear medicine》 |2020年第1期|共13页
作者
Yadav Madhav Prasad; Ballal Sanjana; Bal Chandrashekhar; Sahoo Ranjit Kumar; Damle Nishikant Avinash; Tripathi Madhavi; Seth Amlesh;
展开▼
作者单位

All India Inst Med Sci Dept Nucl Med New Delhi India;

All India Inst Med Sci Dept Nucl Med New Delhi India;

All India Inst Med Sci Dept Nucl Med New Delhi India;

All India Inst Med Sci Dept Med Oncol New Delhi India;

All India Inst Med Sci Dept Nucl Med New Delhi India;

All India Inst Med Sci Dept Nucl Med New Delhi India;

All India Inst Med Sci Dept Urol New Delhi India;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词
Lu-177-PSMA-617; metastatic castration-resistant prostate cancer; radioligand therapy;

机译：Lu-177-PSMA-617;转移性阉割抗性前列腺癌;放射性配体疗法;

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Lu-177-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients [J] . Yadav Madhav Prasad, Ballal Sanjana, Bal Chandrashekhar, Clinical nuclear medicine . 2020,第1期

机译：Lu-177-PSMA-617放射性配体治疗转移阉割前列腺癌患者的疗效和安全性
2. Lu-177-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney [J] . Zhang Jingjing, Kulkarni Harshad R., Singh Aviral, The Journal of Nuclear Medicine . 2019,第11期

机译：Lu-177-PSMA-617在转移性阉割的前列腺癌患者中患有单一功能肾脏的放射性配体治疗
3. Ga-68-PSMA PET/CT for monitoring response to Lu-177-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer [J] . Heinzel Alexander, Boghos Dima, Mottaghy Felix M., European Journal of Nuclear Medicine and Molecular Imaging . 2019,第5期

机译：GA-68-PSMA PET / CT用于监测Lu-177-PSMA-617抗血液抗动性前列腺癌患者的Lu-177-PSMA-617疗法的响应
4. Improving Efficacy of Metastatic Tumor Segmentation to Facilitate Early Prediction of Ovarian Cancer Patients' Response to Chemotherapy [C] . Gopichandh Danala, Yunzhi Wang, Theresa Thai, Biophotonics and immune responses XII . 2017

机译：提高转移性肿瘤分割的功效，以促进卵巢癌患者对化疗的反应的早期预测
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer [O] . Daniel Groener, Cam Tu Nguyen, Justus Baumgarten, 2021

机译：177Lu-PSMA-617患者的血液安全性177LU-PSMA-617抗性前列腺癌患者的放射性疗法
7. Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy [O] . Finn Edler von Eyben, Harshad R. Kulkarni, Richard P. Baum 2020

机译：转移程度预测存活作为转移性阉割前列腺癌的患者用177LU-PSMA放射性配体疗法治疗

Efficacy and Safety of Lu-177-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

摘要

著录项

相似文献

相关主题

期刊订阅